Mereo BioPharma receives second Nasdaq bid price compliance period to February 16, 2027
Mereo BioPharma Group plc was told by Nasdaq that it has not yet regained the $1.00 minimum bid price required for continued listing, but it qualifies for an additional 180-day period, running to February 16, 2027. The notice has no immediate effect on the listing of its American Depositary Shares, though a failure to regain compliance by then would lead to a delisting notice that the company could appeal.
Key points
- Nasdaq's first notice, dated February 17, 2026, set an initial compliance deadline of August 17, 2026.
- On August 18, 2026, Nasdaq issued a second notice granting an additional 180 calendar days, until February 16, 2027.
- Regaining compliance requires a closing bid price of at least $1.00 per share for 10 consecutive business days.
- The company says the listing is unaffected for now and that it may consider options to regain compliance.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.